Protein A will keep its key role in therapeutic mAb production but next generation biotherapeutics will see Protein L become increasingly import says GE Healthcare.
A long dead cocker spaniel will play a key role in helping people avoid the flu this winter after a landmark approval from the US FDA for Novartis’ cell culture based vaccine plant.
Small biotechs should consider buying mothballed plants when scaling-up according to Protein Sciences, which says an ex-Pfizer facility was key to accelerating production of its vaccine Flublok.
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
Horizon, which supplies genomics research services, has bought cell-screening business CombinatoRx from Zalicus for £4.74m ($8m) and plans more acquisitions.
Bioprocessing instrument manufacturer Waters has reported a flat Q1, but management predicts new products and a delayed release of capital from large pharma will lead to growth in 2014.
Biopharma is ramping up the outsourcing of some of the easier tests while tasks such as downstream process development and QbD services are being outsourced less, according to a new survey.
A ‘spinning membrane’ technology could provide an automated solution to the manual problem of cell washing in both upstream and downstream processes says Fresenius Kabi.
Thermo Fisher has launched a pump technology designed for applications across the bioprocessing production line and usable with "all" bioprocessing tech.
Development of new anti-choloesterol drugs containing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting monoclonal antibodies could double Repligen Bioprocessing’s earning power, according to a Jefferies analyst.
Northwest Biotherapeutics, which is developing personalized immune therapies for brain cancer patients, has raised $32m to fund expansion of its manufacturing operations in Europe.
Adaptimmune has selected Biolife’s cryopreservation media for its genetically modified T-cell receptor (TCR) product citing its ability to retain viability and potency.
Novasep has reported a 14 percent growth in its biopharma business driven in part by demand for downstream manufacturing and its continuous chromatography systems.
Researchers are developing a cellulose filter paper they claim is at least as effective at removing viruses from biopharmaceutical production streams as currently available industrial systems.
Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told Biopharma-Reporter.com in an exclusive interview.
Less H5N1 influenza vaccine than expected will be available in Japan this year after downstream processing problems at a plant being set up by Daiichi Sankyo.
Watson-Marlow Pumps Group (WMPG) has bought single-use connection technology developer Bio Pure Technology in a deal designed to bolster its biopharmaceutical manufacturing portfolio.
Outdated technology is one of the greatest challenges in creating next-generation biodrugs, says Jonathan Robinson, who is leading the development of a £38m ($63m) national biomanufacturing hub in the UK.
Downstream processing techs are harder to use and the focus of less innovation than systems employed upstream says the team developing the UK's new National Biologics Manufacturing Centre.
Cobra says it will no longer need to rely on third-parties for its biologics quality control tests after receiving an extension to its GMP certification at a Swedish facility.
BioOutsource says it has quadrupled its revenue from biologics testing and biosimilar characterisation in the last 18 months and is opening a new facility to cope with continued demand.
Sanofi and French biopharma Transgene will soon begin construction on their new €10m ($13.5m) manufacturing plant, which will produce viral vectors for Transgene's targeted cancer immunotherapy, TG4010.
Buying ATMI will help Pall fill gaps in its up and downstream biomanufacturing tech offerings but the deal does not rule out other acquisitions says CEO, Larry Kingsley
Last year Octapharma filed the world’s first ‘truly human’ recombinant Factor VIII clotting protein for EMA review and invited BioPharma-Reporter.com to visit the Swedish site where it makes the haemophilia treatment using HEK cells.
Technology firm Upfront Chromatography has exited the biopharmaceutical manufacturing market after selling its protein purification business to Therapure Biopharma.
US biopharma company Repligen has completed a 9,000 square foot expansion of its facilities in Massachusetts to meet growing customer demand for disposable chromatography columns and warehousing.
DSM says its new biomanufacturing facility will benefit the Australian biotech sector, overcoming the problems of distance with foreign contract manufacturers.
The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.
Increasing interest in biopharmaceuticals has led to significant CMO investments and upgrades with Recipharm, Vetter and Aesica upping their fill/finish game this week.
A new filter tech developed by Pall Life Sciences attracted a lot of attention at the Biotechnica trade show in Germany this week with some attendees describing it as the industry's first truly ‘single-use’ TFF module.
The US Department of Health and Human Services has awarded almost $40m (29m Euros) in contracts to four contract flu vaccine manufacturers as part of an effort to increase fill and finish capacity by 20%.
Sartorius Stedim Biotech (SSB) has launched a new range of culture media dishes designed cut the risk of contamination during lab analysis of facility microbiological QC samples.